Tenet Healthcare
THC on NYSE. General medical & surgical hospitals, nec. Market value $20.9bn.
Price checks use the past 12 months to June 2026. Quality checks use five annual reports, the latest for the year to December 2025.
Should I look at this?
Worth a closer look
Why it could be worth it
What to watch out for
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $14.47 of spare cash in the past 12 months. A savings account pays about $4.
You pay 7.0 years of operating profit for the business. The average large US company costs around 18.
Each dollar kept in the business earns 16 cents a year. Above 10 is good.
Quality score: 75 of 100. Price score: 100 of 100. Our list needs 70 on quality and 60 on price.
$259.47 a share, 65% above its 1-year low
Over the past year the price has ranged from $157.58 to $283.05.
Pays no dividend
Prices from Monday’s close (5 October).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $19.5bn | $19.2bn | $20.6bn | $20.7bn | $21.3bn |
| Operating margin | |||||
| Operating margin | 14.7% | 12.2% | 12.2% | 28.8% | 16.5% |
| Debt to equity | |||||
| Debt to equity | 15.22 | 13.20 | 9.33 | 3.16 | 3.12 |
| Shares outstanding | |||||
| Shares outstanding | 0.11bn | 0.10bn | 0.10bn | 0.09bn | 0.08bn |
Health checks
- Free cash flow positive5 of 5 years
- Accounting looks honest (Beneish)Not enough data
- Financial strength (Piotroski)6 of 7 checks we could run
- Profit backed by cash (accruals)Yes
- Debt3.12× equity
- Revenue growth, five yearsSlow, 3.9% a year
- Buying back its own sharesYes, 26% fewer since 2021
The quarter to June 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $5.6 billion last quarter, up 7% on a year ago.
- Profit: $826 million, up 187% on a year ago.
- It keeps 21 cents of each $1 of sales as operating profit, up from 18 cents a year earlier.
- Spare cash over the past 12 months: $3 billion, up from $1.6 billion.
- 9% fewer shares than a year ago. Each share owns a bit more of the company.
- Debt is $11.1 billion more than cash, up from $10.6 billion a year ago.
- Sales grew on a year ago in each of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| September 2024 | $5.1bn |
| December 2024 | $5.1bn |
| March 2025 | $5.2bn |
| June 2025 | $5.3bn |
| September 2025 | $5.3bn |
| December 2025 | $5.5bn |
| March 2026 | $5.4bn |
| June 2026 | $5.6bn |
| Quarter to | Amount |
|---|---|
| September 2024 | $472m |
| December 2024 | $318m |
| March 2025 | $406m |
| June 2025 | $288m |
| September 2025 | $342m |
| December 2025 | $371m |
| March 2026 | $702m |
| June 2026 | $826m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 17 February 2026
- Next quarterly (estimated, 10-Q)
- 28 October 2026
Who owns it
7 long-term investors we follow own it, unchanged from 7 last quarter. 680 funds in all.
- Harris Associates (Oakmark)Bill Nygren
- Value
- $448,992
- Share of fund
- <0.1%
- Auxier Asset ManagementJeff Auxier
- Value
- $233,850
- Share of fund
- <0.1%
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Boston PartnersBoston Partners team | $829m | 0.7% | Added |
| Glenview Capital ManagementLarry Robbins | $418m | 8.4% | Added |
| LSV Asset ManagementJosef Lakonishok | $50m | <0.1% | Added |
| Gotham Asset ManagementJoel Greenblatt | $33m | <0.1% | Added |
| First Eagle Investment ManagementMatthew McLennan | $3m | <0.1% | Added |
| Harris Associates (Oakmark)Bill Nygren | $448,992 | <0.1% | |
| Auxier Asset ManagementJeff Auxier | $233,850 | <0.1% |
Largest holders overall
- BlackRock$1.6bn
- Price T Rowe Associates$1.5bnAdded
- Boston Partners$829mAdded
- Vanguard Portfolio Management$793m
- FMR$747mCut
- Vanguard Capital Management$729m
- PeakShares$515mAdded
- State Street$515m
- Glenview Capital Management$418mAdded
- Geode Capital Management$353mCut
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
4 investors own more than 5%.
- BlackRock, Inc.Passive investor10.0%+1.2 ptsSince 31 August 2026
- T. Rowe Price Associates, Inc.Passive investor9.2%Since 30 June 2026
- Vanguard Capital ManagementPassive investor5.3%Since 31 March 2026
- FMR LLCPassive investorat least 4.6%(filed with 1 related holder)Since 30 June 2026
- Invesco Ltd.Passive investorSold down below 5%Since 31 March 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
BlackRock, Inc. Passive investor | 10.0%+1.2 pts | 31 August 2026 | |
T. Rowe Price Associates, Inc. Passive investor | 9.2% | 30 June 2026 | |
Vanguard Capital Management Passive investor | 5.3% | 31 March 2026 | |
FMR LLC Passive investor | at least 4.6% (filed with 1 related holder) | 30 June 2026 | |
Invesco Ltd. Passive investor | Sold down below 5% | 31 March 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 14 sold $72m.
- KERREY J ROBERTDirectorSold
- Date
- 14 September 2026
- Shares
- 12,010
- Price
- $263.72
- Value
- $3m
- MARK RICHARD JDirectorSold
- Date
- 10 September 2026
- Shares
- 10,000
- Price
- $263.42
- Value
- $3m
- West NadjaDirectorSold
- Date
- 2 September 2026
- Shares
- 1,152
- Price
- $258.80
- Value
- $298,138
- Foo Lisa YEVP, Chief Operating OfficerSold
- Date
- 31 August 2026
- Shares
- 24,000
- Price
- $266.32
- Value
- $6m
- Sutaria SaumyaCEO, DirectorSold
- Date
- 25 August 2026
- Shares
- 50,000
- Price
- $274.02
- Value
- $14m
- HANEY CECIL DDirectorSold
- Date
- 24 August 2026
- Shares
- 1,300
- Price
- $278.03
- Value
- $361,439
- Sutaria SaumyaCEO, DirectorSold
- Date
- 24 August 2026
- Shares
- 50,000
- Price
- $278.71
- Value
- $14m
- Romo TammyDirectorSold
- Date
- 7 August 2026
- Shares
- 2,500
- Price
- $260.83
- Value
- $652,075
- Romo TammyDirectorSold
- Date
- 6 August 2026
- Shares
- 4,922
- Price
- $264.15
- Value
- $1m
- Blunt RoyDirectorSold
- Date
- 5 August 2026
- Shares
- 600
- Price
- $262.68
- Value
- $157,608
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 14 September 2026 | KERREY J ROBERT Director | Sold | 12,010 | $263.72 | $3m |
| 10 September 2026 | MARK RICHARD J Director | Sold | 10,000 | $263.42 | $3m |
| 2 September 2026 | West Nadja Director | Sold | 1,152 | $258.80 | $298,138 |
| 31 August 2026 | Foo Lisa Y EVP, Chief Operating Officer | Sold | 24,000 | $266.32 | $6m |
| 25 August 2026 | Sutaria Saumya CEO, Director | Sold | 50,000 | $274.02 | $14m |
| 24 August 2026 | HANEY CECIL D Director | Sold | 1,300 | $278.03 | $361,439 |
| 24 August 2026 | Sutaria Saumya CEO, Director | Sold | 50,000 | $278.71 | $14m |
| 7 August 2026 | Romo Tammy Director | Sold | 2,500 | $260.83 | $652,075 |
| 6 August 2026 | Romo Tammy Director | Sold | 4,922 | $264.15 | $1m |
| 5 August 2026 | Blunt Roy Director | Sold | 600 | $262.68 | $157,608 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 17 Feb 2026, plus the 10-Q filed 29 Jul 2026 and 7 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- It carries a lot of debt: 3.1× its equity.
Whether the price already reflects the risks is what the deep dive is for.
What changed in the risks this year
Companies must list what could hurt them each year. These are the parts that changed since last year’s report.
Economic conditions and other factors have had, and may in the future have, an adverse impact on our business.
Could happenRisks we face during periods of economic weakness and high unemployment in the areas where we operate include potential declines in the population covered under managed care contracts, increased patient decisions to postpone or cancel elective and non-emergency healthcare procedures (including delaying surgical procedures), which may lead to poorer health and higher‑acuity interventions, potential increases in the uninsured and underinsured populations, increased adoption of health plan structures that shift financial responsibility to patients, and further difficulties in collecting patient co-pays and deductibles. Any significant deterioration in the collectability of patient accounts receivable could adversely affect our cash flows, results of operations and liquidity.
Read moreRecent and potential future changes to healthcare laws, regulations and policies could have an adverse effect on our business.
Could happenMoreover, once the OBBBA is implemented, the Congressional Budget Office anticipates that millions of individuals could lose health insurance between now and 2034. At this time, we cannot estimate the OBBBA’s impact, nor can we predict the timing of that impact, on our future business, financial condition or results of operations, however, we may experience decreased payments (including supplemental payments) from Medicare, Medicaid and other government programs, as well as delays in the timing of payments to our facilities.
Read more
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.